AISAP Cardio vs Cleerly ISCHEMIA
AI Verdict
Choose AISAP Cardio if…
Choose AISAP Cardio if you need rapid, AI-powered cardiac diagnostic assessments directly at the patient's bedside using point-of-care ultrasound. This tool is ideal for early detection of structural heart disease and heart failure, providing comprehensive measurements and automated reports in acute or time-sensitive clinical settings.
View AISAP Cardio →Choose Cleerly ISCHEMIA if…
Choose Cleerly ISCHEMIA if you require a detailed, non-invasive assessment of coronary artery ischemia and plaque characteristics from a CCTA scan. This AI tool is best suited for physicians planning personalized diagnosis and treatment for heart disease, offering vessel-level ischemia likelihood, stenosis severity, and 3D models of coronary arteries.
View Cleerly ISCHEMIA →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AISAP Cardio | Cleerly ISCHEMIA |
|---|---|---|
| Pricing | Unknown | Contact for details |
| Deployment | Cloud-based | Web-based platform; data transfer via Cleerly Proxy (VPN or virtual appliance) |
| FDA Status | 1 AI-estimated | 1 AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AISAP CardioAISAP Cardio focuses on point-of-care ultrasound (POCUS) with AI-powered interpretation and automated report generation at the bedside, suggesting a highly integrated and immediate workflow for clinicians performing scans. This direct integration into the examination process at the point of care may offer a slightly more streamlined immediate user experience compared to Cleerly ISCHEMIA's web-based platform, although both aim for seamless integration into existing workflows.
Clinical Value
TieBoth tools are FDA-cleared and provide significant clinical value in distinct areas of cardiac diagnosis. AISAP Cardio offers rapid, comprehensive assessments for structural heart disease and heart failure using POCUS, while Cleerly ISCHEMIA provides non-invasive ischemia detection, FFR estimation, and plaque characterization from CCTA scans. They address different, yet equally critical, diagnostic needs within cardiology.
Pricing & Value
TieNeither tool provides publicly available pricing information, requiring direct contact for details. Without transparent pricing, it is impossible to conduct a head-to-head comparison of their cost-effectiveness or overall value proposition. Therefore, a definitive winner cannot be determined in this dimension.
Enterprise Readiness
Cleerly ISCHEMIACleerly ISCHEMIA explicitly states it is HIPAA compliant and has a Business Associate Agreement (BAA), which are critical assurances for enterprise adoption in healthcare. While AISAP Cardio's description implies these are likely in place as an FDA-cleared medical device, Cleerly's explicit confirmation, along with its robust data transfer via Cleerly Proxy, gives it a slight edge in stated enterprise readiness and compliance transparency.
Innovation
TieBoth tools demonstrate significant innovation by applying AI to advanced cardiac diagnostics. AISAP Cardio innovates by bringing AI-powered comprehensive assessments to point-of-care ultrasound, enabling rapid bedside decision-making. Cleerly ISCHEMIA is innovative in its ability to non-invasively estimate fractional flow reserve and characterize coronary plaque from CCTA, providing deeper insights beyond traditional stenosis assessment.
Support & Docs
TieNeither the provided structured facts nor readily available public information from web searches offer specific details regarding the support models, documentation availability, or training programs for either AISAP Cardio or Cleerly ISCHEMIA. Without comparable information on these aspects, it is not possible to distinguish between the two tools.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AISAP Cardio | Cleerly ISCHEMIA |
|---|---|---|
| Name | AISAP Cardio | Cleerly ISCHEMIA |
| Description | FDA-cleared, AI-powered point-of-care ultrasound (POCUS) software platform that provides rapid, comprehensive cardiac diagnostic assessments and measurements, enabling early detection of structural heart disease and heart failure at the bedside. | FDA-cleared AI tool that analyzes CCTA scans to non-invasively determine the likelihood of coronary artery ischemia at a vessel level, aiding physicians in personalized diagnosis and treatment planning for heart disease. |
| Company | Aisap | Cleerly |
| Categories | Cardiology AI | Cardiology AI, Radiology & Imaging AI |
| Key Features | AI-powered interpretation for early cardiac disease detection; Comprehensive cardiac ultrasound software package; Automated generation of analyses, interpretations, and reports; Assessment of valvular pathologies (mitral, tricuspid, aortic regurgitation, aortic stenosis); Measurement of Left Ventricle Ejection Fraction (LVEF); Measurement of right and left ventricular dimensions, atrial areas, ascending aorta diameter, and IVC diameter; Vendor-agnostic and scalable solution; Integration with existing clinical workflows, EHR/EMR, and PACS. | AI-enabled CCTA analysis; Non-invasive fractional flow reserve (FFR) estimation; Vessel-level ischemia likelihood determination; Coronary plaque characterization (volume, type, location); Stenosis severity assessment; 3D digital models of coronary arteries; Comprehensive interactive web-based reports; Integration with PowerScribe via API. |
Videos
Demos, reviews, and walkthroughs featuring AISAP Cardio and Cleerly ISCHEMIA.
Frequently Asked Questions
More Comparisons
More matchups featuring AISAP Cardio or Cleerly ISCHEMIA
Backers
Who funded each tool's parent company.